Jazz Pharmaceuticals Gets $500 Million Term Loan for Gentium Buy

Jazz Pharmaceuticals Plc (JAZZ), a manufacturer of products for treating narcolepsy, cancer, pain and psychosis, obtained a commitment for a $500 million loan to back its purchase of Gentium SpA.

Barclays Plc is providing the loan, which along with cash and a revolving line of credit will support the acquisition, the Dublin, Ireland-based company said in a statement today distributed by PR Newswire. The transaction, which is valued at about $1 billion, is expected to close in the first quarter.

Jazz Pharmaceuticals has a $555.8 million term loan that expires in June 2018 and pays interest at 2.75 percentage points more than the London interbank offered rate with a 0.75 percent minimum on the lending benchmark, according to data compiled by Bloomberg. The company’s $200 million credit line, which matures in June 2017, was undrawn as of Sept. 30, the data show.

Interest on the add-on loan is expected in the range of 3 percent to 3.5 percent, the company said in a regulatory filing. After closing of the transaction, adjusted earnings before interest, taxes, depreciation and amortization is expected to be less than 2.5 times.

In a revolving line of credit, money may be borrowed again once it’s repaid; in a term loan it can’t.

To contact the reporter on this story: Krista Giovacco in New York at kgiovacco1@bloomberg.net

To contact the editor responsible for this story: Faris Khan at fkhan33@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.